Angus C. Russell
CIK 1534002 · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TXMD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3280 BAYSHORE BOULEVARD
BRISBANE, CA 94005
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Director | 87,500 | $1.00 | $87.8K | -$14.0K | 8 | 2026-07-02 |
| GPCR | Director | — | $21.05 | — | $0 | 3 | 2026-06-18 |
| Revance Therapeutics, Inc. (RVNC) Delisted | Director | 0 | $3.65 | $0 | $100.7K | 14 | 2025-02-06 |
| TXMD | Director | 5,792 | $1.78 | $10.3K | $422.7K | 15 | 2022-10-03 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 0 | $0.34 | $0 | -$6.7K | 13 | 2020-11-16 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 67,500 | — | — | $191.5K | 5 | 2018-07-03 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Director | 5,114 | — | — | $150.0K | 3 | 2013-11-13 |
Recent Filings · Page 2 of 7
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-03 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2022-08-22 | TXMD | Exer (M) | +1,984 | $0 | EDGAR |
| 2022-07-06 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2022-05-13 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-06 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +6,059 | $0 | EDGAR |
| 2021-12-15 | Revance Therapeutics, Inc. (RVNC) Delisted | Buy (P) | +6,400 | $100.7K | EDGAR |
| 2021-08-12 | TXMD | Exer (M) | +96,864 | $0 | EDGAR |
| 2021-07-02 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2021-07-01 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2021-06-30 | LCTX | Mixed | +20,000 | $40.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.